Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio

J Clin Oncol. 2016 Mar 20;34(9):1017-8. doi: 10.1200/JCO.2015.65.0028. Epub 2016 Jan 19.

Authors

Alice Indini¹, Massimo Di Nicola², Michele Del Vecchio², Filippo De Braud²

Affiliations

¹ Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy alice.indini@istitutotumori.mi.it.
² Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.

PMID: 26786928
DOI: 10.1200/JCO.2015.65.0028

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents / adverse effects*
Female
Humans
Immunosuppressive Agents / therapeutic use*
Male
Melanoma / drug therapy*
Skin Neoplasms / drug therapy*

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Immunosuppressive Agents